TECN logo
TECN
Tecan Group

Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
16 Mar 25
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
CHF 225.02
30.8% undervalued intrinsic discount
31 Jul
CHF 155.70
Loading
1Y
-50.6%
7D
-6.0%

Author's Valuation

CHF 225.0

30.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates7

Shared on01 May 25
Fair value Decreased 6.05%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25
Fair value Decreased 0.083%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Increased 6.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more